Vivet Therapeutics Presents Breakthrough Data on AAV Neutralizing Antibody Depletion at ESGCT 2025
Sevilla, October 2025 – At the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Vivet Therapeutics shared new clinical data with its VTX-PID proprietary imlifidase formulation, highlighting the effective reduction of neutralizing antibodies (NAbs) against AAV3B in healthy volunteers. Key Findings: Vivet Therapeutics remains committed to advancing innovative therapies and […]
Join us at ESGCT 2025 in Sevilla
Join us at ESGCT 2025 in Sevilla for an important presentation by Jean-Philippe Combal from Vivet Therapeutics on October 9th at 10:00am CET during the session entitled Immune responses to gene therapy. https://lnkd.in/enSxNwzFLearn how VTX-PID (imlifidase) enables optimal depletion of anti-AAV3B neutralizing antibodies in human subjects, expanding eligibility for future systemic AAV-based gene therapies through innovative dose-ranging and […]
Our Pilot study of Cu64 data in Heterozygous Wilson’s Disease patients
We are excited to share our paper on Pilot clinical study showing abnormal copper metabolism in healthy Wilson disease heterozygote subjects, accepted to CTSJournal. See it here : https://lnkd.in/e-rzZnXp #ASCPTJournalFamily – Wilson Disease Association 64Cu has been used for decades to study WD, however clear data are lacking to document the rate of fecal elimination […]
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotechcompany developing novel and long-lasting gene therapies for rare inherited liver metabolicdisorders, today announces that it will be presenting key pre-clinical findings for VTX-806, itsgene therapy program for the treatment of Cerebrotendinous Xanthomatosis (CTX), at TheLiver Meeting presented by the American Association for […]
💗Pink October💗
In collaboration with @Courir pour Elles, @Vivet_tx participated in an 8km walk/run to raise #BreastCancer Awareness and Prevention. Join #TeamVivet in the cause as we rack up steps👟for #CourirPourElles’ 💗Pink 💗Challenge during #PinkOctober. Also known as ‘le Défi Rose’, the Challenge helps raise #BreastCancerAwareness and highlights the role a healthy lifestyle plays in #cancer prevention.
Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
Paris, France, October 22, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the presentation of three posters demonstrating key pre-clinical findings for its gene therapy program, VTX-806 for the treatment of Cerebrotendinous Xanthomatosis (CTX), a study on S/MAR-containing AAV vector […]
Leukodystrophy Awareness Month
📢 Leukodystrophy Awareness Month takes place throughout the whole month of September and is a time to raise awareness about these devastating rare conditions! Together 🤝 let’s shine a light💡 and increase understanding of leukodystrophy, a group of rare genetic metabolic disorders affecting the central nervous system. Leukodystrophies are characterized by the abnormal growth of […]
The @European Commission has granted Orphan Drug Designation (#ODD) to our gene therapy product, VTX-806, for the treatment of cerebrotendinous xanthomatosis (#CTX), a rare #neurodegenerativedisease in patients.
European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX) • Pre-clinical data of VTX-806 in mice demonstrated normalization of metabolic parameters in blood and brain, and of upregulated compensatory enzymes• EUR 4.9 million funding provided by French Government to develop VTX-806 as an effective treatment […]
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
Paris, France, July 16, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is delighted to announce that its Co-Founder & Chief Scientific Officer, Dr Gloria Gonzalez-Aseguinolaza, PhD, has been honored with the Rosalind Franklin Society (RFS) Special Award in Science given […]
Characteristics of patients with Wilson Disease in the United States: An insurance claims database study
We are delighted to share our findings in a peer reviewed paper published in the World Journal of Hepatology, titled ‘Characteristics of patients with Wilson Disease in the United States: An insurance claims database study.’
